SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-010958
Filing Date
2024-08-06
Accepted
2024-08-06 08:02:06
Documents
14
Period of Report
2024-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20240806x8k.htm   iXBRL 8-K 32727
2 EX-99.1 kala-20240806xex99d1.htm EX-99.1 133960
  Complete submission text file 0001558370-24-010958.txt   295475

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20240806.xsd EX-101.SCH 3259
4 EX-101.LAB kala-20240806_lab.xml EX-101.LAB 15264
5 EX-101.PRE kala-20240806_pre.xml EX-101.PRE 9656
17 EXTRACTED XBRL INSTANCE DOCUMENT kala-20240806x8k_htm.xml XML 4630
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 241177170
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)